Clinical Study on Skin Lightening With elure(TM) Published in the Journal of Cosmetic Dermatology Shows Significant Superiori...
15 Febrero 2012 - 6:00AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today the publication of results from a
clinical study evaluating the skin lightening efficacy and safety
of its elure™ Advanced Skin Lightening product (lignin peroxidase
cream) compared with 2% hydroquinone cream. The study, which
demonstrated significantly faster and superior skin lightening
results with elure, was published in the December 2011 issue of the
peer-reviewed Journal of Cosmetic Dermatology. The Journal of
Cosmetic Dermatology is the official journal of The International
Academy of Cosmetic Dermatology (IACD).
The publication, which is titled "A Randomized and
Placebo-Controlled Study to Compare the Skin Lightening, Efficacy,
and Safety of Lignin Peroxidase Cream Versus 2% Hydroquinone
Cream," is currently available on the journal's online website. The
single-center, randomized, double-blind, placebo-controlled study
included 51 patients, all of which were Asian women. Patients were
randomized to receive day and night applications of elure Advanced
Skin Lightening products on one randomly selected side of their
face, and either 2% hydroquinone cream or placebo on the other side
of their face.
The results from the study demonstrated a statistically
significant change from baseline in the melanin index (as measured
with optical instrumentation) on skin treated with elure Advanced
Skin Lightening products, with a mean reduction of 7.6% (p <
0.001) on Day 31. Melanin is the molecule that accumulates in the
skin to cause a darkened, pigmented or uneven skin tone. This
compares to 2% hydroquinone cream and placebo, both of which did
not provide a statistically significant change from baseline in the
melanin index on Day 31. In addition, dermatologist scoring
demonstrated a significant improvement in overall fairness as early
as Day 8 on skin treated with elure Advanced Skin Lightening
products, which was not observed on skin treated with 2%
hydroquinone cream or placebo in the same timeframe.
Tess Mauricio, MD, founder of Scripps Ranch Dermatology &
Cosmetic Center in San Diego, CA, and lead author of the study,
said, "The results from this study not only demonstrate that elure
is safe and efficacious, but that it represents a significant
breakthrough in skin lightening technology. elure achieved a
statistically significant reduction in melanin after one month,
while hydroquinone, which was previously the most effective
treatment option, did not. elure was also shown to be safe and well
tolerated by patients in the study, providing additional benefits
compared to the known side-effects of hydroquinone. In addition,
some patients in the study achieved significant skin lightening
results in as little as 8 days, which is attributable to the fact
that elure's mechanism of action is to directly decompose melanin
in the skin."
Louis P. Scafuri, Chief Executive Officer of Syneron Medical,
said, "This first peer reviewed publication on elure confirms the
strong early clinical and commercial results that patients have
achieved with the product and further highlights its potential to
become the gold standard for skin lightening and pigmentation
treatments. We expect elure's clinical efficacy will be further
confirmed upon the publication of several ongoing studies with
global key opinion leaders on a variety of pigmentation disorders.
We look forward to leveraging the excellent data published in the
Journal of Cosmetic Dermatology, combined with other future
publications on elure, to broaden awareness of the elure Advanced
Skin Lightening product line."
About Syneron Medical Ltd. Syneron Medical
Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The Company markets, services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide.
Media Contacts: Syneron - Public Relations Email Contact
Investor Contacts: Asaf Alperovitz Chief Financial Officer +
972 73 244 2283 Email: Email Contact Zack Kubow The Ruth Group
646-536-7020 Email: Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024